Selecting a Microbiome CDMO Partner for the Long Term, Arranta Bio Shares (Pharma's Almanac)

Selecting a Microbiome CDMO Partner for the Long Term, Arranta Bio Shares

As more microbiome-based therapies progress through the clinic toward approval for market launch, concerns over the lack of outsourcing capacity for process development and commercial manufacturing of live biotherapeutic products are increasing. Arranta Bio is investing heavily in both its process development and cGMP manufacturing capabilities for the supply of clinical trial material and in a new commercial-ready facility to ensure that companies in the microbiome space have access to the specialized expertise and facilities needed to bring novel medicines to patients.

Since its establishment in 2019, Arranta Bio has focused on serving companies seeking to develop and commercialize therapies targeting the human microbiome. Partnering to secure the deep microbiome expertise that has become the foundation of Arranta was critical, so, in November 2019, Arranta Bio acquired UF Innovate | The Hub resident client Captozyme, now Oxidien Pharmaceuticals, which focused solely on process development and early clinical scale-up of LBPs. Captozyme’s founder Dr. Aaron Cowley (now Arranta’s Chief Scientific Officer) and his team bring to bear more than a decade of institutionalized knowledge and experience gained developing microbiome products that achieve critical product attributes (such as high final form cell viability, long-lasting stability, and the appropriate administration release profile), enabling microbiome products to have the best opportunity for clinical success. 

Learn more about Selecting a Microbiome CDMO Partner for the Long Term, Arranta Bio Shares.
X